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ABSTRACT
Acute graft-versus-host disease (aGVHD) still remains one of the life-threatening complications following
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Immunomodulation of alloreactive donor T
cell responses, as well as cytokine secretion is a potential therapeutic approach for the prevention of aGVHD.
The synthetic triterpenoid, CDDO (2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid), exhibits potent antitu-
mor activity and has also been shown to mediate anti-inflammatory and immunomodulatory effects. We
therefore wanted to assess the effects of CDDO on early lethal aGVHD. In this study, we found that CDDO
significantly inhibited in vitro mixed lymphocyte responses and preferentially promoted the apoptosis of
proliferating but not resting alloreactive T cells. Using a full major histocompatibility complex (MHC)-
disparate murine aGVHD model, we found that the administration of CDDO immediately after transplanta-
tion significantly decreased liver pathology as determined by histologic assessment and prolonged survival in
mice. Importantly, administration of CDDO did not adversely impair donor myeloid reconstitution as deter-
mined by peripheral blood cell count and the extent of donor chimerism. These findings indicate that CDDO
has a significant immunomodulatory effects in vitro and on early lethal aGVHD development, particularly
affecting the liver, in a murine allo-HSCT model.
© 2007 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Acute graft-versus-host disease (aGVHD), a result
f alloreactive donor T cells in the hematopoietic
raft, is a life-threatening complication of allogeneic
ematopoietic stem cell transplantation (allo-HSCT).
lthough donor T cells can mediate graft-versus-
umor (GVT) effects, which improve the outcome of
alignant diseases after allo-HSCT treatment, sepa-ation of the beneﬁcial GVT from aGVHD is still a tilemma [1]. With aGVHD development, the primary
arget organs (gut, liver, and skin) are injured by both
ellular and inﬂammatory cytokine effectors. There-
ore, immunomodulation of alloreactive donor T cells
esponses as well cytokine secretion may represent a
ealistic approach to the prevention of aGVHD [2-4].
The synthetic triterpenoid, 2-cyano-3, 12-di-
xooleana-1, 9-dien-28-oic acid (CDDO), is a mul-
ifunctional molecule that exerts numerous biologic
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K. Sun et al.522ffects including anti-inﬂammatory, potent antipro-
iferative and apoptosis-inducing activities [5]. It has
een shown that CDDO is effective in inducing apo-
tosis in leukemic and multiple myeloma cells in vitro
6,7]. It was reported that CDDO can sensitize leuke-
ia cells to apoptosis involving downregulation of
LIP and sensitization to TRAIL [8]. In addition, as
he ligand for the peroxisome proliferator activator
eceptor-gamma (PPAR-), one of the mechanisms by
hich CDDO can induce apoptosis in tumor cells
nvolves upregulation of the PPAR- pathway [9].
ecently, PPAR- has also been found to broadly
egulate inﬂammatory responses [10-12]. In a patho-
en-driven animal ileitis model, CDDO prevented
leitis development through the global downregula-
ion of inﬂammatory cytokines and chemokines [13].
hus, CDDO is an attractive candidate for adminis-
ration in an allo-HSCT setting because of its direct
nd indirect antitumor effects, together with its po-
ential immunomodulating properties.
We report here that the CDDO signiﬁcantly in-
ibited in vitro mixed lymphocyte responses and pref-
rentially promoted apoptosis in proliferating but not
esting alloreactive T cells. Moreover, CDDO admin-
stered immediately following murine allo-HSCT re-
ulted in signiﬁcant reduction of early aGVHD lethal-
ty with signiﬁcant protection of liver pathology, with
o observed adverse effects on myeloid recovery and
onor chimerism.
ATERIALS AND METHODS
nimals
Female C57BL/6 (B6, H2b) and BALB/c (H2d)
ice were purchased from the Animal Production
rea of the National Cancer Institute (Frederick,
D). Animals were kept in speciﬁc pathogen-free
onditions. All animal protocols were approved and in
ivo studies were performed at University of Nevada,
eno. Mice were between 8 and 13 weeks of age at the
tart of the experiments.
eagents and Media
CDDO was manufactured through the NIH RAID
rogram and kindly provided by Drs. E. Sausville and
. Sporn. CDDO was prepared in a vehicle solution of
0% DMSO (Sigma, St Louis, MO), 10% Cremophor
L (Sigma), and 80% Dulbecco’s phosphate-buffered
aline solution (DPBS) (Mediatech, Herndon, VA) at
concentration of 1.2 mg/mL. Brieﬂy, CDDO was
eighed out and dissolved into the DMSO, followed by
he addition of the Cremophor EL and DPBS. The
olution was then sonicated for 30 minutes, sterile ﬁl-
ered, and stored at 4°C for up to 2 months prior to use.
he proteasome inhibitor, bortezomib, was kindly pro-
ided by Millennium Pharmaceuticals (Cambridge, wA). Stock bortezomib solution (2.603  103 M) was
repared in Dulbecco phosphate-buffered saline solu-
ion (PBS) and stored at70°C for up to 2 months prior
o use. Bortezomib solutions were protected from light
t all times. All mitogen assays and mixed lymphocyte
eactions (MLRs) were cultured in complete medium
ontaining RPMI 1640 (Cambrex, Walkersville, MD),
upplemented with 10% fetal bovine serum (Gemini,
oodland, CA), 10 mM HEPES, 2 mM L-glutamine
Cambrex), 100 U/mL penicillin/streptomycin (Medi-
tech), 1 mM nonessential amino acids, 1 mM sodium
yruvate, and 5  105 M 2-ME (Invitrogen, Grand
sland, NY).
itogen Assay
Naïve unfractionated BALB/c splenocytes were
lated in quadruplicate in 96-well plates at a concen-
ration of 2.5  105 cells per well, and were treated
ith 2 g/mL Concanavalin A (ConA) (Sigma) and
arious doses of CDDO in complete media. Plates
ere incubated for 24 hours at 37°C and 5% CO2, and
ere then pulsed with 1 Ci/well [3H] thymidine (MP
iomedicals, Solon, OH) for an additional 16 hours
rior to harvesting and reading on a 1450 Microbeta
rilux scintillation counter (Wallac, Turku, Finland).
n Vitro MLR Cultures
To monitor primary responses, responder cells
BALB/c splenocytes, 2.5  105/well) and stimulator
ells (30 Gy irradiated B6 splenocytes, 2.5 105/well)
ere plated in 96-well plates in quadruplicate in com-
lete media. The plates were incubated at 37°C with
% CO2 for 3-7 days, then pulsed with [
3H]-thymi-
ine (1 Ci/well) for 16-18 hours prior to harvesting
nd counting.
TT Colorimetric Assay
A colorimetric assay using 3-(4,5-dimethylthia-
oyl)-2,5-diphenyltetrazolium bromide (MTT) was
erformed as per the manufacturer’s instruction (Roche
iagnostics GmbH, Mannheim, Germany). Brieﬂy,
6 spleen cells (2  105cells/well) were plated in
6-well plates with complete media and 2 g/mL
onA in triplicate in the presence of various concen-
rations of CDDO or Bortezomib and incubated at
7°C in a 5% humidiﬁed CO2 incubator for 48 hours.
hen, 10 L of MTT labeling reagent (5 mg/mL) was
dded to each well and incubation was continued for a
urther 4 hours at 37°C. In each well, 100 L/well of
olubilization solution (10% SDS in 0.01 M HCl) was
dded. After overnight incubation at 37°C in a 5%
umidiﬁed CO2 incubator, plates were read at 550 nm
n a Versamax tunable microplate reader (Molecular
evices Corporation, Sunnyvale, CA). The reference
avelength was 650 nm.
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CDDO in T Cell Responses 523FSE Labeling and Apoptosis Assessment
BALB/c splenocytes were labeled with 2.5 M
arboxy-ﬂuorescein diacetate succinimidyl ester
CFSE) (Molecular Probes, Eugene, OR) according
o the manufacturer’s instructions. CFSE labeled
ALB/c splenocytes were plated at a concentration of
.5 105 cells per well along with 2.5 105 irradiated
30 Gy) T cell-depleted B6 splenocytes and various
oncentrations of CDDO. T cells were depleted from
6 splenocytes by incubating with anti-Thy 1.2 mAb
clone 30H-12), followed by incubation with rabbit
omplement. After 3 days in culture, the cells were
arvested and labeled with PE-Cy5 conjugated CD4
nd CD8 antibodies and PE Annexin V (BD Pharm-
ngen, San Diego, CA). During ﬂow cytometry anal-
sis, gates were drawn on CD4 or CD8 positive cells,
hen gated on CFSEhigh/CFSElow cells, and the per-
entage of Annexin V positive cells determined.
omplete Blood Count (CBC)
nd Flow Cytometry
Peripheral blood, spleen, and bone marrow sam-
les were collected on day 14 after transplantation.
lood samples were collected in microvette capillary
lood collection tubes (Sarstedt, Germany) and the
BC analyzed on a Hemavet 950 (Drew Scientiﬁc,
xford, CT). Donor cell chimerism was determined
y ﬂow cytometry. Cells (1  106) were labeled with
uorescence, either FITC- or PE-conjugated anti-
ouse mAbs (FITC-H2Dd, PE-H2Kb) purchased
rom BD Biosciences (San Diego, CA) for 2-color
ow cytometry. Nonspeciﬁc binding was corrected
ith isotype-matched controls. All results were ob-
ained on a BD FACScan ﬂow cytometer (Becton
ickinson, San Jose, CA).
ell Preparation
Bone marrow cell (BMC) suspensions were pre-
ared by gently releasing cells from the femurs, tibiae,
nd backbones into DPBS with a mortar and pestle.
plenocyte preparations were prepared by gently
rushing the spleens. Preparations were ﬁltered to
emove debris and washed twice in DPBS for injec-
ion. Cell counts were performed on a Coulter Z1 cell
ounter (Coulter Electronics, Hialeah, FL).
n Vivo Studies
B6 recipient mice received myeloablative doses
900 or 950 cGy) total body irradiation (TBI) from a
37Cs source. Irradiation was followed by the infusion
f 1.0  107 BALB/c BMCs into the tail vein with or
ithout BALB/c splenocytes (SCs; 35-40  106 cells)
s a source of allogeneic T cells. Recipient B6 mice
hen received a vehicle control or CDDO intraperi-
oneally with the dose range (240-480 g) given daily orom days 0 through 1 posttransplantation. Mice
ere monitored daily. All moribund mice were hu-
anely killed. All experiments were performed at least
times with 5 to 13 mice per group.
istology
The murine GVHD target tissues (liver, colon,
nd small intestine) were ﬁxed in 10% formalin, em-
edded in parafﬁn, sectioned, and stained with hema-
oxylin and eosin. Tissue sections were evaluated by a
athologist and GVHD changes were graded in coded
ashion. For liver specimens we used the pathologic
rading system reported by Li et al [14] with modiﬁ-
ations. Liver GVHD was graded based on degree of
epatocyte apoptosis, venulitis, bile duct inﬂamma-
ion, and lobular hepatitis. If there was a discordance
n severity of these parameters, the lesion was graded
ased on the highest degree. Score 0 was given when
o apoptotic hepatocytes were seen, no mononuclear
ells were found in or surrounding the terminal he-
atic vein and within bile ducts, and no lobular in-
ammatory foci were found. Score 1 was given when
are apoptotic hepatocytes were seen, 25% of the
ortal tract was occupied by inﬂammatory cells, only a
ew mononuclear cells were found in or surrounding
he terminal hepatic vein, and 10 lobular inﬂamma-
ory foci were found in a 100  ﬁeld. Score 2 was
iven when occasional apoptotic hepatocytes were
een, 25%-50% of the portal tract was occupied by
nﬂammatory cells, mononuclear cells surrounded the
ein without forming a conﬂuent layer, and 10-20
obular inﬂammatory foci were found in a 100  ﬁeld.
core 3 was given when frequent apoptotic hepato-
ytes were seen, 50%-75% of the portal tract was
ccupied by inﬂammatory cells, a single conﬂuent
ayer of mononuclear cells surrounded the vein, and
0-30 lobular inﬂammatory foci were found in a 100 
eld. Score 4 was given when numerous apoptotic
epatocytes were seen, 50% of the portal tract was
ccupied by inﬂammatory cells, the cellular inﬁltrate
bscured the vein wall, and 30 lobular inﬂammatory
oci were found in a 100  ﬁeld. A similar grading
ystem was developed for intestinal specimens. Intes-
inal GVHD was graded based on degree of individual
rypt cell necrosis, goblet cell depletion, cryptitis,
rypt abscesses, distortion of crypt architecture in-
luding crypt dropout, loss of villi in the small intes-
ine, and sloughing of the colonic mucosa. Score 0 was
iven when no individual crypt cell necrosis was seen
nd normal intestinal architecture was preserved. One
olymorphonucleated leukocyte (PMNL) per 5 or
ore epithelial cells was considered a normal feature.
core 1 was given when rare individual crypt cell
ecrosis was seen in the background of preserved
ormal intestinal architecture. Score 2 was given when
ccasional individual crypt cell necrosis was seen, focal
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K. Sun et al.524reas with more than 1 PMNL per 5 epithelial cells
cryptitis) without crypt abscess formation were seen
n the background of preserved intestinal architecture.
core 3 was given when frequent individual necrotic
rypt cells were seen, areas with more than 1 PMNL
er 5 epithelial cells (cryptitis) with focal crypt abscess
ormation were seen in the background of preserved
ntestinal architecture. Score 4 was given when numer-
us necrotic individual crypt cells were seen, prominent
reas of cryptitis and crypt abscess, crypt dropout, loss of
illi (in small intestine), conﬂuent destruction of glands,
oss of mucosa with formation of granulation tissue and
seudomembrane were detected.
ytokine Analysis
Blood samples were obtained on day5 after trans-
lantation. Serum levels of tumor necrosis factor alpha
TNF-) were determined by ELISA (R&D Systems,
inneapolis, MN) as per manufacturer’s instructions.
tatistics
Survival data were plotted by the Kaplan-Meier
ethod and analyzed by the log-rank test. T cell
roliferation was evaluated with the one-way ANOVA
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igure 1.CDDO inhibits the mitogen and alloantigen-induced T ce
lus 4 different concentrations of CDDO or vehicle and cultured f
igniﬁcantly inhibited in a dose-dependent manner in the presenc
rradiated B6 splenocytes at a 1:1 ratio for 4 days (B) or 3-7 days (
escribed in Materials and Methods. T cell proliferation was signiﬁc
DDO (signiﬁcant differences compared with vehicle control, *P 
resented. (C) B6 splenocytes (2  105 cells/well) were exposed to C
ndividual vehicles. Plates were incubated at 37°C and 5% CO2 fo
igniﬁcantly inhibited in the presence of 250 and 500 nM CDDO (P
ortezomib (P  0.05) compared to their vehicle controls (ANOVA withnd Dunnett’s Multiple Comparison Test. CBC and
ow cytometry data was analyzed with the unpaired
tudent’s t test with the Welch correction. Pathology
cores were evaluated with the Mann-Whitney test.
-value .05 in a 2-tailed analysis was considered
igniﬁcant.
ESULTS
DDO Can Inhibit Mitogen or Alloantigen-induced
cell Proliferation In Vitro in a
ose-Dependent Manner
CDDO has been demonstrated to have potent
ntiproliferative and anti-inﬂammatory activities
13,15,16]. Therefore, we ﬁrst assessed the effects of
DDO on murine T cell response to either mitogen
r alloantigen in vitro. The results demonstrate that
DDO can signiﬁcantly inhibit proliferative T cell
esponses to the mitogen ConA (Figure 1A; one-way
NOVA, P  0.01) or alloantigen in the MLR in a
ose-dependent manner and at concentrations as low
s 0.15 M (Figure 1B and D). We then compared the
fﬁcacy of CDDO with the proteasome inhibitor,
ortezomib, on T cell response to the mitogen (Figure
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ys as described in Materials and Methods. T cell proliferation was
0.4 M CDDO. (B, D) BALB/c splenocytes were cultured with
n pulsed with [3H] thymidine for 16 hours prior to harvesting as
hibited in a dose-dependent manner in the presence of 0.15 M
and **P  0.01). Results from 1 of 4 independent experiments are
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CDDO in T Cell Responses 525C). Bortezomib was far superior to CDDO on T cell
rowth inhibition at the concentrations tested. There-
ore, CDDO was capable of inhibiting mitogen stim-
lated and allogeneic MLR-induced murine T cell
roliferation in vitro, although it is not as potent when
ompared to the proteasome inhibitor bortezomib.
DDO Selectively Induces Higher Apoptosis in
roliferating But Not Resting T Cells In Vitro
We next assessed the mechanism by which
DDO signiﬁcantly suppressed allogeneic MLR-in-
uced murine T cell alloreactivity in vitro. CSFE dye
ilution was used for assessment of cell division and
nnexin V binding was used as a marker of apoptosis.
he results demonstrate that the addition of CDDO
nto the MLR resulted in signiﬁcant increases in
poptosis of alloreactive CD4 and CD8 T cells
one-way ANOVA, P  0.05). Of interest, predomi-
ate apoptotic cells were in the CSFElo population
Figure 2A and B), suggesting that the proliferating T
ells were primarily targeted. These results indicate
hat CDDO is capable of suppressing alloreactive T
ell responses, resulting from, in part, the selective
epletion of alloreactive T cells.
DDO Administration Reduces Acute GVHD
ethality in Mice
After observing that CDDO can signiﬁcantly in-
ibit alloreactivity in vitro, we then proceeded to ex-
mine the effects of CDDO in vivo on murine
GVHD induction and progression. In these studies,
fter myeloablative pretransplantation conditioning
ith TBI, recipient B6 (H2b) mice received 10 million
MCs with or without 35-40 million SCs (as a source
f alloreactive T cells) from fully major histocompat-
bility complex (MHC)-mismatched BALB/c (H2d)
onors. Then, a vehicle control or CDDO was ad-
inistered intraperitoneally to the recipients immedi-
tely following transplantation for 2 days. We have
ound that this regimen resulted in the greatest
GVHD protection compared with more prolonged
reatment with CDDO (data not shown). No morbid-
ty was observed in the mice that received allo-HSCT
ith BMCs alone followed by treatment with CDDO
r vehicle control (Figure 3A). Among the lethally
rradiated mice that underwent transplantation with
MCs and SCs, the mice that received the vehicle
ontrol succumbed rapidly to early aGVHD. In
arked contrast, the mice that received CDDO ex-
ibited delayed development of aGVHD and signiﬁ-
ant improvement in survival (Figure 3A, P  0.001).
reatment with CDDO led to signiﬁcant decreases in
he serum TNF- production that occurs in mice on
ay 5 after myeloablative conditioning and allo-
SCT (Figure 3B, P  0.05). In addition, whereas
oth groups of the mice receiving BMCs and SCs ihowed signiﬁcant weight loss from aGVHD, the
ice treated with CDDO did not experience as severe
f a weight loss early posttransplantation as the vehi-
le-treated mice (Figure 3C, P 0.001). These results
emonstrate that early administration of CDDO is
apable of reducing the severity of early, lethal
GVHD after allo-HSCT in mice correlating with the
eduction of serum TNF- levels.
DDO Administration Results in Decreased
epatic Injury But Not Intestinal Injury
n Mice with GVHD
We next examined the effects of CDDO admin-
stration on target organ injury during aGVHD. Sam-
les of liver and gut were harvested on day 8 after
llo-HSCT and evaluated for GVHD-associated his-
opathologic changes. Histopathologic assessment re-
ealed that signiﬁcant decreases in liver damage oc-
urred in mice following CDDO administration
igure 2. Proliferating, and not resting, T cells are highly sensitive
o CDDO-mediated apoptosis. CFSE-labeled BALB/c splenocytes
ere incubated with irradiated T cell-depleted B6 splenocytes at a
:1 ratio with a dose range of CDDO as described in Materials and
ethods. After 3 days in culture, cells were harvested and ana-
yzed by ﬂow cytometry. Cells were ﬁrst gated on CD4 or CD8
xpression, then gated on CFSEhigh or CFSElow staining, and
nalyzed for annexin V binding in proliferating or resting T cells.
A) Proportionally greater increases in annexin V binding were
bserved on proliferating (CFSElow) compared with nonalloreac-
ive (CFSEhigh) CD4 T cells with exposure to 0.25 M, 0.5 M,
nd 0.75 M CDDO. (B) Proportionally greater increases in
nnexin V binding were observed on proliferating (CFSElow)
ompared with nonalloreactive (CFSEhigh) CD8 T cells with
xposure to 0.25 M, 0.5 M, and 0.75 M CDDO. *Signiﬁcant
ifferences of annexin V binding on CDDO-exposed T cells
ompared with control (P  0.05). Results from 1 of 3 indepen-
ent experiments are presented.mmediately after transplantation compared with ve-
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K. Sun et al.526icle control administration (Figure 4A, 4E and 4F).
urprisingly, CDDO administration did not signiﬁ-
antly reduce the gastrointestinal tract damage when
ompared with mice that received the vehicle control
Figure 4B, 4C and 4D). These results suggested that
he reduction of aGVHD lethality in mice is associ-
ted with decreases in liver lesions and that CDDO
pparently is speciﬁc for the liver with regards to
VHD protection.
DDO Administration Does Not Adversely
ffect Donor Engraftment and Peripheral
lood Recovery in allo-HSCT Mice
We then assessed the effects of CDDO adminis-
ration on donor engraftment and peripheral blood
ecovery in allo-HSCT mice. Mice were analyzed at
ay 14 after transplant for myeloid reconstitution
nd donor engraftment. We found CDDO adminis-
ration had no signiﬁcant effect on peripheral white
lood cell (WBC) or platelet (PLT) recovery post-
llo-HSCT compared with mice that received vehicle
ontrol (Figure 5A). Likewise, no signiﬁcant differ-
nces in donor cell chimerism were observed in mice
hat received CDDO post-allo-HSCT (Figure 5B).
igure 3. CDDO administration immediately after transplantation
urvival. B6 (H2b) mice received TBI (900 cGy) followed by infusio
reated with vehicle control or CDDO (240 g/dose) twice a day intr
f CDDO protected mice from early GVHD mortality. Signiﬁca
ompared with GVHD control (vehicle control-treated) mice (; P
igniﬁcant decrease in serum TNF- levels of mice on day5 post-
C) Signiﬁcant protection from GVHD associated weight loss on d
f 3 independent experiments are presented.hese results demonstrated that CDDO administra- tion to recipients of allo-HSCT does not impair do-
or engraftment or myeloid reconstitution.
ISCUSSION
The use of allo-HSCT in cancer treatment has
een seriously hampered by the occurrence of
GVHD and cancer relapse. Therefore, assessment of
gents with known antineoplastic activity that also
ossess antiproliferative and anti-inﬂammatory activ-
ty may be useful in both the prevention of aGVHD
nd cancer relapse. In this study, we have examined
he use of the synthetic triterpenoid, CDDO, as a new
herapeutic to decrease alloantigen-induced T re-
ponse and reduce early aGVHD lethality. The num-
er of alloreactive T cells plays a critical role in the
nduction and development of aGVHD [1,3,4]. The
ata presented here demonstrate that CDDO can in-
ibit alloantigen-induced T cell proliferation in vitro,
n part by selectively targeting alloreactive T cells. In
ivo data further conﬁrmed that treatment of mice with
DDO immediately following allo-HSCT led to signif-
cant improvement in survival from early aGVHD.
The mechanism for the modulation of allo-reac-
in delayed development of GVHD and signiﬁcant improvement in
 106 BALB/c (H2d) BMC and 35  106 BALB/c SC. Mice were
neally on day 0 and day1 for a total of 4 doses. (A) Administration
rovement in survival were observed in CDDO-treated mice ()
1). Results from 1 of 3 independent experiments are presented. (B)
n mice that received CDDO compared to mice treated with vehicle.
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CDDO in T Cell Responses 527y CDDO is not deﬁnitively known, in part, resulting
rom the multifunctional properties of CDDO. One is
hat inhibiting alloreactive T cell response may be
ttributable to inhibitory effects of nuclear factor
igure 4. CDDO administration results in decreased hepatic injury
950 cGy), followed by infusion of 10 106 BALB/c (H2d) BMC an
240 g/dose) three times a day intraperitoneally on day 0 and day
B) of mice that received BMC alone or with splenocytes, followed
f representative gut tissue sections. Mice that received BMC with
ith spleen cells followed by CDDO (D) demonstrated similar pro
rographs of representative liver tissue sections. Mice that receive
xpensive GVHD with bile duct proliferation, vasculitis, lobular hep
ith spleen cells followed by CDDO (F) demonstrated preserved p
poptotic cells. H&E staining, original magniﬁcation 500.appa B (NF-	B) as CDDO has recently been dem- anstrated to inhibit NF-	B on tumor cell lines [17].
nother mechanism may be by the induction of im-
unosuppressive cytokines. Transforming growth
actor beta (TGF-
) has been shown to attenuate
intestinal injury in mice with GVHD. B6 (H2b) mice received TBI
106 BALB/c SC. Mice were treated with vehicle control or CDDO
a total of 2 doses. (A, B). Pathology scores in the liver (A) and gut
inistration of vehicle control or CDDO. (C, D) Photomicrographs
cells followed by vehicle control (C) and mice that received BMC
tissue damage with numerous apoptotic bodies. (E, F). Photomi-
with spleen cells followed by vehicle control (E) demonstrated
and numerous apoptotic cells. In contrast, mice that received BMC
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 production by intraepithelial lympho-
ytes to prevent ileitis through the global downregu-
ation of inﬂammatory cytokines and chemokines [13].
s a ligand for the PPAR- [9,20], CDDO may also
odulate immune responses and inhibit T cell prolif-
ration. Dose-dependent inhibition of T cell prolifer-
tion by CDDO in an MLR may suggest the reduc-
ion of the allo-reactive response is from direct
ytotoxicity on proliferating T cells.
As shown in Figure 3, CDDO-dependent reduc-
igure 5. CDDO administration does not adversely affect donor e
f 10  106 BALB/c (H2d) BMC and 40  106 BALB/c SC. Mice
ntraperitoneally on day 0 and day 1 for a total of 4 doses. Blood,
onor cells on day 14 posttransplantation (4-6 mice/group). (A) CBC
B) The frequency of donor cells in the bone marrow and spleen foll
rom 1 of 2 independent experiments are presented.ion of GVHD lethality can be observed when CDDO [s administered within a dose range of 240-480 g
aily from days 0 through 1 posttransplantation,
ndicating that the development of GVHD can be
elayed by CDDO when administered immediately
fter allo-HSCT. We further found that extended
dministration of CDDO while aGVHD was ongoing
id not lead to increased protection of GVHD (data
ot shown). This is consistent with other agents such
s proteasome inhibitors, which also were found to be
rotective only if given immediately after allo-HSCT
ent. B6 (H2b) mice received TBI (900 cGy) followed by infusion
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arrow, and spleen were collected and analyzed for engraftment of
eters were not signiﬁcantly affected by CDDO treatment in mice.
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city [23], and it has been demonstrated that inhibition
f NF-	B can exacerbate gut injury in other models
hile preventing systemic inﬂammation [24]. In this
etting, extended treatment with CDDO may maxi-
ize the apoptotic potential of cellular and inﬂamma-
ory cytokine mediated allo-reactive response to gut
amage. It may possibly explain our ﬁnding of de-
reased hepatic histopathology but not intestinal his-
opathology in these mice with aGVHD after treat-
ent with CDDO. It is also possible that CDDO can
ffect chemokine production responsible for donor
llo-reactive T cells homing to the liver.
In summary, the data presented here demonstrate
hat CDDO signiﬁcantly inhibits allo-reactive T cell
esponses in MLR cultures, and when administered
mmediately following murine allo-HSCT, results in
igniﬁcant inhibition of early aGVHD with no dele-
erious effects on donor engraftment. Besides a direct
ntitumor effect, CDDO has also been reported to be
ble to sensitize leukemia cells to apoptosis through
ownregulation of FLIP and sensitization to TRAIL.
herefore, future studies will determine whether
DDO can reduce aGVHD lethality with increased
raft-versus-tumor effect in tumor-bearing recipients.
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